R&D Spending Showdown: Summit Therapeutics Inc. vs Sarepta Therapeutics, Inc.

Biotech R&D: Sarepta's Aggressive Growth vs. Summit's Steady Climb

__timestampSarepta Therapeutics, Inc.Summit Therapeutics Inc.
Wednesday, January 1, 20149423100015635076
Thursday, January 1, 201514639400023943601
Friday, January 1, 201618827200023689111
Sunday, January 1, 201716670700041006114
Monday, January 1, 201840184300051379106
Tuesday, January 1, 201956090900032705593
Wednesday, January 1, 202072234300053274000
Friday, January 1, 202177118200085352000
Saturday, January 1, 202287709000051999000
Sunday, January 1, 202387738700059471000
Loading chart...

Unleashing insights

R&D Spending Trends in Biotech: A Tale of Two Companies

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. has consistently outpaced Summit Therapeutics Inc. in R&D investments. From 2014 to 2023, Sarepta's R&D expenses surged by over 830%, peaking in 2023 with a staggering 878 million dollars. In contrast, Summit's R&D spending grew by approximately 280%, reaching nearly 59 million dollars in the same year. This significant disparity highlights Sarepta's aggressive pursuit of cutting-edge therapies, while Summit adopts a more conservative approach. As the biotech landscape evolves, these spending patterns may influence their respective positions in the market, with Sarepta potentially leading the charge in groundbreaking treatments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025